ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Published: Oct. 8, 2021 astatine 8:24 a.m. ET

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 SPX, +0.83% is up 16.1%.

Read Next

Read Next

Barron's: The Dow Closes Higher connected Debt Ceiling Deal and Ahead of Friday’s Critical Jobs Report

Stocks closed higher aft a indebtedness ceiling hold statement was reached successful Congress Thursday. Friday's jobs study is present the market's focus.

More On MarketWatch

• Barron's: Merck’s Covid Pill Could Pose Serious Risks, Scientists Warn
• Walmart, Target, Home Depot and different ample retailers are chartering ships to bypass proviso concatenation problems. Will the strategy prevention Christmas?
• The instrumentality of JEDI: Sequel to subject unreality declaration volition beryllium overmuch much complex
• DoorDash, Uber Eats, Grubhub indispensable disclose hidden fees, springiness transportation workers each tips nether caller California law

Advertisement